E-LIB Suche - Ergebnisse für: Moriwaki, K.

1

EE289 Cost-Effectiveness Analysis of Blinatumomab for Advan..:

Ozeki, S ; Moriwaki, K ; Morimoto, K.
Value in Health. 27 (2024) 6 - p. S111 , 2024

Link: https://doi.org/10.1016/..

2

EE158 Economic Evaluation of Duvelisib Versus Ofatumumab in..:

Shimizu, K ; Moriwaki, K ; Morimoto, K.
Value in Health. 27 (2024) 6 - p. S86-S87 , 2024

Link: https://doi.org/10.1016/..

3

EE504 Cost-Effectiveness Analysis of Tremelimumab As First-..:

Sakai, R ; Moriwaki, K ; Morimoto, K.
Value in Health. 27 (2024) 6 - p. S150 , 2024

Link: https://doi.org/10.1016/..

4

EE508 Cost-Effectiveness Analysis of Pembrolizumab for Adva..:

Taniguchi, S ; Moriwaki, K ; Morimoto, K.
Value in Health. 27 (2024) 6 - p. S150-S151 , 2024

Link: https://doi.org/10.1016/..

5

HTA42 Vignette-Based Estimation of Utilities in Patients wi..:

Yamaguchi, M ; Moriwaki, K ; Shimozuma, K
Value in Health. 27 (2024) 6 - p. S252 , 2024

Link: https://doi.org/10.1016/..

6

PCR154 Health State Utility Values in COVID-19: A Vignette ..:

Noto, S ; Shimozuma, K ; Iwatani, T...
Value in Health. 27 (2024) 6 - p. S325 , 2024

Link: https://doi.org/10.1016/..

7

EE66 Cost-Effectiveness Analysis of Pembrolizumab + Chemoth..:

Akai, M ; Moriwaki, K ; Morimoto, K.
Value in Health. 27 (2024) 6 - p. S69 , 2024

Link: https://doi.org/10.1016/..

8

EE498 Economic Evaluation of Nanoparticle Albumin-Bound pac..:

Fukui, Y. ; Chen, W. ; Maeda, T....
Value in Health. 26 (2023) 6 - p. S150 , 2023

Link: https://doi.org/10.1016/..

9

EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan ..:

Yamaguchi, M. ; Maeda, T. ; Morimoto, K....
Value in Health. 26 (2023) 6 - p. S106 , 2023

Link: https://doi.org/10.1016/..

10

Cardiac-specific deletion of myosin phosphatase targeting s..:

Ye, Z ; Okamoto, R ; Ito, H...
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

11

EE42 Economic Evaluation of Donafenib Versus Sorafenib in F..:

Tsuyuki, T. ; Morimoto, K. ; Maeda, T....
Value in Health. 26 (2023) 6 - p. S67 , 2023

Link: https://doi.org/10.1016/..

12

EE164 Cost-Effectiveness of Nivolumab Plus Ipilimumab in Ga..:

Fukuda, T. ; Morimoto, K. ; Maeda, T....
Value in Health. 26 (2023) 6 - p. S89 , 2023

Link: https://doi.org/10.1016/..

13

EE380 Cost-Effectiveness Analysis of Erlotinib Plus Bevaciz..:

Yoshioka, S. ; Chen, W. ; Maeda, T....
Value in Health. 26 (2023) 6 - p. S129 , 2023

Link: https://doi.org/10.1016/..

14

EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-L..:

Shibata Maeda, Y.T. ; Chen, W. ; Morimoto, K...
Value in Health. 26 (2023) 6 - p. S150-S151 , 2023

Link: https://doi.org/10.1016/..

15

POSC280 Economic Evaluation of Nivolumab Plus Ipilimumab in..:

Maeda, T ; Morimoto, K ; Mo, X..
Value in Health. 25 (2022) 1 - p. S188-S189 , 2022

Link: https://doi.org/10.1016/..